Multiple myeloma (A cancer arising from plasma cells)

ESMO 2023: Highlights and analysis

Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer

Shared decision making (Patient-oncologist)

Lung Cancer

Head and Neck Cancers

Breast Cancer

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC